DDN on Twitter: “#CRDMO LakePharma, Inc. to manufacture Akston Biosciences Corporation’s #COVID19 #vaccine AKS-452 for Phase 1/2 #ClinicalTrials. Shelf-stable Fc fusion vs #SARSCoV2 #spike #RBD designed to induce mixed Th1/Th2 #immune response”